Below you find a list of some of the most relevant publications from the Moriggl research team. For a complete list of publications by Dr. Richard Moriggl please follow this link.
Nivarthi H, Gordziel C, Themanns M, Kramer N, Eberl M, Rabe B, Schlederer M, Rose-John S, Knösel T, Kenner L, Freund P, Aberger F, Han X, Kralovics R, Dolznig H, Jennek S, Friedrich K,Moriggl R. Oncotarget. PMID: 27191495 [Impact Factor: 5.0] (2016)
Minas TZ, Surdez D, Javaheri T, Tanaka M, Howarth M, Kang HJ, Han J, Han ZY, Sax B, Kream BE, Hong SH, Çelik H, Tirode F, Tuckermann J, Toretsky JA, Kenner L, Kovar H, Lee S, Sweet-Cordero EA, Nakamura T, Moriggl R, Delattre O, Üren A. Oncotarget. PMID: 27191748 [Impact Factor: 5.0] (2016)
Gotthardt D, Putz EM, Grundschober E, Prchal-Murphy M, Straka E, Kudweis P, Heller G, Bago-Horvath Z, Witalisz-Siepracka A, Cumaraswamy AA, Gunning PT, Strobl B, Müller M, Moriggl R, Stockmann C, Sexl V. Cancer Discovery PMID: 26873347 [Impact Factor 19.8] (2016)
Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Colaguori R, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger MW. Leukemia. PMID: 25134459 (2015) [Impact Factor 12.1]
Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischmann AG, Zhou W,Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, Neuberg DS, Levine RL, Moriggl R, Müller M, Gray NS, Jamieson CHM, Weng AP, Staudt LM, Druker BJ, Look AT. Cancer Discovery, PMID: 23471820 [Impact Factor 19.8] (2013)
Warsch W, Grundschober E, Berger A, Gille L, Cerny-Reiterer S, Tigan AS, Hoelbl-Kovacic A, Valent P, Moriggl R, Sexl V. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukemia. Oncotarget,PMID: 23458731 [Impact Factor: 4.8] (2013)
Laimer D, Dolznig H, Kollmann K, Vesely PW, Schlederer M, Merkel O, Schiefer AI, Hassler MR, Heider S, Amenitsch L, Thallinger C, Staber PB, Simonitsch-Klupp I, Artaker M, Lagger S, Turner SD, Pileri S, Piccaluga P, Valent P, Messana K, Landra I, Weichhart T, Knapp S, Shehata M, Todaro M, Sexl V, Höfler G, Piva R, Medico E, Ruggeri BA, Cheng M, Eferl R, Egger G, Penninger J, Jaeger U, Moriggl R, Inghirami G, & Kenner L. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nature Medicine, 18:1699-704. doi: 10.1038/nm.2966. [Impact Factor: 22.5] (2012)
Musteanu M, Blaas L, Zenz R, Hoffmann T, Grabner B, Schramek D, Kantner HP, Mueller M, Kolbe T, Rülicke T, Moriggl R, Kenner L, Stoiber D, Penninger J, Popper H, Casanova E & Eferl R. A Multi-Hit mouse model to identify cooperating Ras effector pathways in lung cancer, Nature Methods, 9:897-900. doi: 10.1038/nmeth.2130. [Impact Factor: 19.3] (2012)
Kovacic B, Hoelbl A, Litos G, Alacakaptan M, Schuster C, Fischhuber KM, Kerenyi MA, Stengl G, Moriggl R, Sexl V & Beug H. Diverging fates of cells of origin in acute and chronic leukemia. EMBO Molecular Medicine, 4:283-297 [Impact Factor: 10.3] (2012)
Gilbert S, Zhang R, Denson L, Moriggl R, Steinbrecher K, Shroyer N, Lin J & Han X. Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation. EMBO Molecular Medicine, 4:109-24. [Impact Factor: 10.3] (2012)
Friedbichler K, Themanns M, Mueller KM, Schlederer M, Kornfeld JW, Terracciano LM, Kozlov AV, Haindl S, Kenner L, Kolbe T, Mueller M, Snibson KJ, Heim MH & Moriggl R. Growth hormone-induced Stat5 signaling causes gigantism, inflammation and premature death but protects mice from aggressive liver cancer. Hepatology, 55:941—52. [Impact Factor: 11.7] (2012)
Mueller KM, Themanns M, Friedbichler K, Kornfeld JW, Esterbauer H, Tuckermann JP & Moriggl R. Hepatic growth hormone and glucocorticoid receptor signaling in body growth, steatosis and metabolic liver cancer development. Molecular and Cellular Endocrinology, 361:1-11. doi: 10.1016/j.mce.2012.03.026. [Impact Factor: 4.2] (2012) [review article]
Krämer O & Moriggl R. Acetylation and sumoylation control STAT5 activation antagonistically. JAK-STAT 1:3, 203–207; Landes Bioscience, PubMed certification is expected in 2013. [Impact Factor pending] (2012) [review article]
Nivarthi H, Friedbichler K & Moriggl R. Stat5 as a hematopoietic master regulator for differentiation and neoplasia development. Jak-Stat Signaling: from Basics to Disease, edited by Thomas Decker and Mathias Müller. ©2011 Springer 153-169. (2012) [book chapter]